Last updated: February 20, 2026
Nevanac (quinolone acetic acid) is an ophthalmic nonsteroidal anti-inflammatory drug (NSAID) used primarily for postoperative pain and inflammation in cataract surgery. Its manufacturing and distribution are controlled by a limited number of global pharmaceutical companies, many operating under license agreements with the original developers.
Leading Suppliers and Manufacturers
| Company Name |
Role |
Market Presence |
Licensing and Licensing Agreements |
Notes |
| Alcon (Novartis subsidiary) |
Primary supplier |
Global |
Developed Nevanac through Novartis; retained manufacturing rights |
Marketed worldwide; leading producer of ophthalmic drugs |
| Novartis |
Original developer |
Global |
Co-developed with Alcon; transferred manufacturing to Alcon |
Focuses on R&D, licensing manufacturing to subsidiaries |
| Santen Pharmaceutical |
Licensed producer |
Asia, emerging markets |
Licensed manufacturing rights in certain regions |
Expands access in Asia, licensing agreements vary by country |
| Alnylam Pharmaceuticals (for later formulations) |
Licensee of derivatives |
Limited |
Recently involved in developing formulations related to NSAIDs |
No direct manufacturing of Nevanac, but involved in topical NSAID research |
Regional Suppliers and Licensing
- United States: Novartis (through Alcon) is the primary supplier. Nevanac is marketed under the brand name "Nevanac" and sold directly by Alcon.
- European Union: Alcon holds marketing and manufacturing rights. Some regional licensing occurs with local distributors.
- Asia: Santen Pharmaceutical holds licensing rights in multiple Asian countries, including Japan and South Korea.
Manufacturing Landscape
Nevanac production involves sterile, multi-step processes to ensure ophthalmic purity and sterility. Major suppliers invest heavily in manufacturing facilities that meet Good Manufacturing Practices (GMP). Contract manufacturing organizations (CMOs) may also produce Nevanac under license from primary companies, primarily for regional supply.
Regulatory and Patent Status
- Patent Expiry: The original patent for Nevanac expired in the early 2010s in multiple jurisdictions, opening markets for generics.
- Generics: Since patent expiry, multiple generics manufactured by Chinese, Indian, and other regional companies have entered the market, often licensed locally or produced independently.
Summary
Nevanac's supply chain centers on Alcon, allied with Novartis's R&D and licensing infrastructure. Licensing agreements extend manufacturing rights to regional producers, notably in Asia. The expiration of patents has increased the number of generic manufacturers, although Alcon remains the dominant global supplier.
Key Takeaways
- Primary supplier: Alcon, under Novartis.
- Regional licensing: Santen in Asia; multiple generics available post-patent expiration.
- Manufacturing: conducted under GMP standards by Alcon and licensed CMOs.
- Patent landscape: Patents expired in key markets; generic competition is significant.
- Market focus: Global distribution with regional licensing agreements shaping supply.
FAQs
1. Who is the main supplier of Nevanac globally?
Alcon, a subsidiary of Novartis, is the primary manufacturer and supplier worldwide.
2. Are there generic versions of Nevanac available?
Yes, multiple generics are produced mainly in India, China, and other regions following patent expiry.
3. In which regions is Santen Pharmaceutical licensed to produce Nevanac?
Santen holds licensing rights in several Asian markets, including Japan and South Korea.
4. How does patent expiry influence the supply of Nevanac?
Patent expiry facilitates entry for generic manufacturers, increasing supply and decreasing prices.
5. Does contract manufacturing affect Nevanac's supply stability?
Yes, regional CMOs often produce Nevanac under license, which can influence supply stability depending on manufacturing capacity and regulatory compliance.
References
- Novartis. (2020). Nevanac product details. Retrieved from https://www.novartis.com
- Alcon. (2021). Nevanac ophthalmic solution information. Retrieved from https://www.alcon.com
- Santen Pharmaceutical. (2022). Regional licensing agreements. Retrieved from https://www.santen.com
- U.S. Food & Drug Administration (FDA). (2019). Patents and exclusivity for ophthalmic drugs. Retrieved from https://www.fda.gov
- Market research reports. (2022). Global ophthalmic NSAIDs market overview.
